Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01764854 · ClinicalTrials.gov registry record · Phase 2
Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis
A Phase 2 study of End Stage Renal Disease and ESRD, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
- 3
- Study locations
NCT01764854: Completed Phase 2 study of End Stage Renal Disease and ESRD, sponsored by Ardelyx.
NCT01764854 is a Phase 2 study of End Stage Renal Disease and ESRD that has completed, run by Ardelyx. The registered enrollment target is 88 participants, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01764854, a Phase 2 study of End Stage Renal Disease and ESRD, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis.
Primary Outcome
Patients are weighed pre dialysis prior to their first dialysis of the week. This measure looks at the change in pre-dialysis weight over time
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD1722 (in-patient)
- DRUG Placebo (in-patient)
- DRUG AZD1722 (out-patient)
Study Locations (3)
Arizona
- Southwest Clinical Research Institute - Tempe
Colorado
- Denver Nephrology - Denver
Minnesota
- DaVita Clinical Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT01764854 record still lists
NCT01764854 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 832-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01764854 reports a single indexed study location in Arizona, Colorado, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01764854 about?
NCT01764854 is a clinical study titled "Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis". The purpose of this study is to determine if the study drug is safe, tolerable and active in reducing fluid overload/weight gain between dialysis sessions for patients with End Stage Renal Disease on Hemodialysis.
What is the current status of trial NCT01764854?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2013-01. Estimated completion is 2013-10.
What conditions does trial NCT01764854 study?
This clinical trial studies the following conditions: End Stage Renal Disease, ESRD, Chronic Kidney Disease Stage 5.
What interventions are being tested in trial NCT01764854?
The interventions under investigation include: Placebo (DRUG), AZD1722 (in-patient) (DRUG), Placebo (in-patient) (DRUG), AZD1722 (out-patient) (DRUG).
Who is sponsoring clinical trial NCT01764854?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01764854 being conducted?
This trial has 3 study locations across Arizona, Colorado, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01764854's enrollment target sits among peer trials
88 40th of 86 higher than 47 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
-
Safety and Efficacy of Empagliflozin in Hemodialysis
RECRUITING · Phase 2
-
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
RECRUITING · Phase 2
-
Communication During Hospitalization About Resuscitation Trial
ACTIVE NOT RECRUITING · Phase 2
-
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
COMPLETED · Phase 2
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia